An insight into the metabolic responses of ultra-small superparamagnetic particles of iron oxide using metabonomic analysis of biofluids

Nanotechnology

Volumn 21, Issue 39, 2010, Pages

  Feng, Jianghua ^a,b   Liu, Huili ^b   Zhang, Limin ^b   Bhakoo, Kishore ^c   Lu, Lehui ^d  

^a XIAMEN UNIVERSITY   (China)

^b Wuhan National Laboratory for Optoelectronics   (China)

^c AGENCY FOR SCIENCE   (Singapore)

^d CHANGCHUN INSTITUTE OF APPLIED CHEMISTRY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADVERSE EFFECT; ALLANTOINS; AMINO ACID METABOLISM; BIOFLUIDS; BIOTOXICITY; HIGH RESOLUTION; HUMAN HEALTH; HYDROXYBUTYRATE; IN-VIVO; KETOGLUTARATE; KETONE BODIES; METABOLIC CHANGES; METABOLIC PATHWAYS; METABOLIC PROFILES; METABONOMIC ANALYSIS; METABONOMICS; MULTIVARIATE STATISTICAL ANALYSIS; MYO-INOSITOL; NANO-MATERIALS; NMR ANALYSIS; PHYSIOLOGICAL RESPONSE; PLASMA GLUCOSE; RAT URINE; RENAL AND CARDIAC FUNCTION; SATURATED FATTY ACID; SUPERPARAMAGNETIC PARTICLES; TARGETED CONTRAST AGENTS; TRIACYLGLYCEROLS; ULTRA-SMALL; UNSATURATED FATTY ACIDS; WEALTH OF INFORMATION;

ACETONE; AMINO ACIDS; BODY FLUIDS; FATTY ACIDS; GLUCOSE; GLYCEROL; IRON OXIDES; MAGNETIC RESONANCE IMAGING; MAMMALS; METAL ANALYSIS; MULTIVARIANT ANALYSIS; NUCLEAR MAGNETIC RESONANCE; PHYSIOLOGICAL MODELS; RESONANCE; SUPERPARAMAGNETISM; SURFACE CHEMISTRY; TOXICITY;

METABOLISM;

CONTRAST MEDIUM; MAGNETITE NANOPARTICLE;

ANIMAL; ARTICLE; BLOOD ANALYSIS; CHEMISTRY; DRUG EFFECT; MALE; METABOLOME; METABOLOMICS; METHODOLOGY; MULTIVARIATE ANALYSIS; NUCLEAR MAGNETIC RESONANCE; PLASMA; PRINCIPAL COMPONENT ANALYSIS; RAT; SPRAGUE DAWLEY RAT; URINE;

ANIMALS; BLOOD CHEMICAL ANALYSIS; CONTRAST MEDIA; MAGNETITE NANOPARTICLES; MALE; METABOLOME; METABOLOMICS; MULTIVARIATE ANALYSIS; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PLASMA; PRINCIPAL COMPONENT ANALYSIS; RATS; RATS, SPRAGUE-DAWLEY; URINE;

EID: 77958576318     PISSN: 09574484     EISSN: 13616528     Source Type: Journal    
DOI: 10.1088/0957-4484/21/39/395101     Document Type: Article

References (44)

1. Aitken R J, ChaudhryM Q, Boxall A B A and Hull M 2006 Manufacture and use of nanomaterials: current status in the UK and global trends Occup. Med. 56 300-6
2. Ansemann R 2001 Nanoparticles and nanolayers in commercial applications J. Nanopart. Res. 3 329-36
3. Uwatoku T, Shimokawa H, Abe K, Matsumoto Y, Hattori T, Oi K, Matsuda T, Kataoka K and Takeshita A 2003 Application of nanoparticle technology for the prevention of restenosis after balloon injury in rats Circ. Res. 92 e62-9
4. Metz S, Bonaterra G, Rudelius M, Settles M, Rummeny E J and Dalerup-Link H E 2004 Capacity of human monocytes to phagocytose approved iron oxide MR contrast agents in vitro Eur. Radiol. 14 1851-8
5. Abrams M T et al 2010 Evaluation of efficacy, biodistribution, and inflammation for a potent siRNA nanoparticle: effect of dexamethasone co-administration Mol. Ther. 18 171-80
6. Miyata R, Ueda M, Jinno H, Konno T, Ishihara K, Ando N and Kitagawa Y 2009 Selective targeting by preS1 domain of hepatitis B surface antigen conjugated with phosphorylcholine-based amphiphilic block copolymer micelles as a biocompatible, drug delivery carrier for administration of human hepatocellular carcinoma with paclitaxel Int. J. Cancer 124 2460-7
7. Trickler W J, Nagvekar A A and Dash A K 2008 A novel nanoparticle formulation for sustained paclitaxel delivery AAPS Pharmaceut. Sci. Technol. 9 486-93
8. Bhabra G et al 2009 Nanoparticles can cause DNA damage across a cellular barrier Nat. Nanotechnol. 4 876-83
9. Song Y, Li X and Du X 2009 Exposure to nanoparticles is related to pleural effusion, pulmonary fibrosis and granuloma Eur. Res. J. 34 559-67
10. Halbreich A, Groman E V, Raison D, Bounchaud C and Paturance S 2002 Damage to the protein synthesizing apparatus in mouse liver in vivo by magnetocytolysis in the presence of hepatospecific magnetic nanoparticles J. Magn. Magn. Mater. 248 276-85
11. Dousset V, Ballarino L, Delalande C, Coussemacq M, Canioni P, Petry K G and Caillé J M 1999 Comparison of ultra-small particles of iron oxide (USPIO)-enhanced T2-weighted, conventional T2-weighted, and gadolinium-enhanced T1-weighted MR images in rats with experimental autoimmune encephalomyelitis Am. J. Neuroradiol. 20 223-7
12. Pouliquen D, Le Jeune J J, Perdrisot R, Ermias A and Jallet P 1991 Iron oxide nanoparticles for use as an MRI contrast agent: pharmacokinetics and metabolism Magn. Reson. Imaging 9 275-83
13. Anzai Y et al 2003 Evaluation of neck and body metastases to nodes with Ferumoxtran 10-enhanced MR imaging: phase III safety and efficacy study Radiology 228 777-88
14. Poland C A, Duffin R, Kinloch I, Maynard A, Wallace W A H, Seaton A, Stone V, Brown S, MacNee W and Donaldson K 2008 Carbon nanotubes introduced into the abdominal cavity of mice show asbestos-like pathogenicity in a pilot study Nat. Nanotechnol. 3 423-8
15. Maynard A D et al 2006 Safe handling of nanotechnology Nature 444 267-9
16. Bu Q et al 2010 NMR-based metabonomic study of the sub-acute toxicity of titanium dioxide nanoparticles in rats after oral administration Nanotechnology 21 125105
17. Coen M, Holmes E, Lindon J C and Nicholson J K 2008 NMR-based metabolic profiling and metabonomic approaches to problems in molecular toxicology Chem. Res. Toxicol. 21 9-27
18. 1H NMR spectroscopy Toxicol. Appl. Pharmacol. 234 314-25
19. Wang Y L, Holmes E, Nicholson J K, Cloarec O, Chollet J, Tanner M, Singer B H and Utzinger J 2004 Metabonomic investigations in mice infected with schistosoma mansoni: an approach for biomarker identification Proc. Natl Acad. Sci. USA 101 12676-81
20. Dumas M-E et al 2006 Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice Proc. Natl Acad. Sci. USA 103 12511-6
21. Walsh M C, Brennan L, Malthouse J P G, Roche H M and Gibney M J 2006 Effect of acute dietary standardization on the urinary, plasma, and salivary metabolomic profiles of healthy humans Am. J. Clin. Nutr. 84 531-9
22. Bertram H C, Hoppe C, Petersen B O, Duus J Ø, Mølgaard C and Michaelsen K F 2007 An NMR-based metabonomic investigation on effects on milk and meat protein diets given to 8-year-old boys Br. J. Nutr. 97 758-63
23. Veiseh O et al 2005 Optical and MRI multifunctional nanoprobe for targeting gliomas Nano Lett. 5 1003-8
24. Josephson L, Tung C H, Moore A andWeissleder R 1999 High-efficiency intracellular magnetic labeling with novel superparamagnetic-tat peptide conjugates Bioconjug. Chem. 10 186-91
25. Beckwith-Hall B M, Nicholson J K, Nicholls A W, Foxall P J D, Lindon J C, Connor S C, Abdi M, Connelly J and Holmes E 1998 Nuclear magnetic resonance spectroscopic and principal components analysis investigations into biochemical effects of three model hepatotoxins Chem. Res. Toxicol. 11 260-72
26. Waters N J, Waterfield C J, Farrant R D, Holmes E and Nicholson J K 2005 Metabonomic deconvolution of embedded toxicity: application to thioacetamide hepato- and nephrotoxicity Chem. Res. Toxicol. 18 639-54
27. Bollard M E et al 2005 Comparative metabonomics of differential hydrazine toxicity in the rat and mouse Toxicol. Appl. Pharmacol. 204 135-51
28. 13C NMR spectroscopy of human blood plasma Anal. Chem. 67 793-811
29. 1H NMR spectroscopy of biological fluids Anal. Chem. 68 3370-6
30. Tang H, Wang Y, Nicholson J K and Lindon J C 2004 Use of relaxation-edited one-dimensional and two dimensional nuclear magnetic resonance spectroscopy to improve detection of small metabolites in blood plasma Anal. Biochem. 325 260-72
31. Bulte J W M, Ma L D, Magin R L, Kamman R L, Hulstraert C E, Go K G, The T H and de Leij L 1993 Selective MR imaging of labeled human peripheral blood mononuclear cells by liposomes mediated incorporation of dextran-magnetic particles Magn. Reson. Med. 29 32-7
32. Okon E, Pouliquen D, Okon P, Kovaleva Z V, Stepanova T P, Lavit S G, Kudryavtsev B N and Jallet P 1994 Biodegradation of magnetite dextran nanoparticles in the rat. A histologic and biophysical study Lab. Invest. 71 895-903
33. Briley-Saebo K, Bjørnerud A, Grant D, Ahlstrom H, Berg T and Kindberg G M 2004 Hepatic cellular distribution and degradation of iron oxide nanoparticles following single intravenous injection in rats: implications for magnetic resonance imaging Cell Tissue Res. 316 315-23
34. Shibata K and Onodera M 1992 Changes in the conversion rate of tryptophan-nicotinamide according to dietary fat and protein levels Biosci. Biotechnol. Biochem. 56 1104-8
35. Meijer A J and Verhoeven A J 1984 N-acetylglutamate and urea synthesis Biochem. J. 56 559-60
36. Young E G, Wentworth H P and Hawkins W W 1944 The absorption and excretion of allantoin in mammals J. Pharmacol. Exp. Ther. 81 1-9
37. Nicholson J K, Timbrell J A and Sadler P J 1985 Proton NMR spectra of urine as indicators of renal damage mercury-induced nephrotoxicity in rats Mol. Pharmacol. 27 644-51
38. McGarry J D and Foster D W 1980 Regulation of hepatic fatty acid oxidation and ketone body production Annu. Rev. Biochem. 49 395-420
39. Berg J M, Tymoczko J L and Stryer L 2003 Biochemistry 5th edn (New York: Freeman)
40. Kasuya F, Yamaoka Y, Osawa E, Igarashi K and Fukui M 2000 Difference of the liver and kidney in glycine conjugation of ortho-substituted benzoic acids Chem. Biol. Interact. 125 39-50
41. Griffin J L, Mann C J, Scott J, Shoulders C C and Nicholson J K 2001 Choline containing metabolites during cell transfection: an insight into magnetic resonance spectroscopy detectable changes FEBS Lett. 509 263-6
42. Feng J H, Zhao J, Hao F H, Chen C, Bhakoo K and Tang H R 2010 NMR-based metabonomic analyses to effects of ultra-small superparamagnetic particles of iron oxide (USPIO) on macrophage metabonomes J. Nanopart. Res. doi:10.1007/s11051-010-9959-5
43. Seed M, Hoppichler F, Reaveley D, McCarthy S, Thompson G R, Boerwinkle E and Utermann G 1990 Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia New Engl. J. Med. 322 1494-9
44. Bathen T F, Engan T, Krane J and Axelson D 2000 Analysis and classification of proton NMR spectra of lipoprotein fractions from healthy volunteers and patients with cancer or CHD Anticancer Res. 20 2393-408